Development of novel antihyperlipidemic combination of atorvastatin and bar antagonist 16-dehydropregnenlone (80-574): pharmacokinetic and pharmacodynamic drug-drug interaction

被引：0
|
作者：
Bhatta, Rabi Sankar [1 ]
Puri, Anju [2 ]
Khanna, Ashok K. [2 ]
Pratap, Ram [3 ]
Jani, G. K. [1 ]
机构：
[1] CSIR Cent Drug Res Inst, Pharmacokinet & Metab Div, Lucknow, Uttar Pradesh, India
[2] CSIR Cent Drug Res Inst, Biochem, Lucknow, Uttar Pradesh, India
[3] CSIR Cent Drug Res Inst, Med & Proc Chem, Lucknow, Uttar Pradesh, India
来源：
DRUG METABOLISM REVIEWS | 2016年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P239
引用
收藏
页码：138 / 138
页数：1
相关论文
共 4 条
  • [1] Pharmacokinetic and pharmacodynamic drug-drug interaction of Nomilin with atorvastatin in hyperlipidemic mice
    Ding, Yan
    Guan, Huida
    Yan, Yingxuan
    Chen, Yan
    Huang, Cheng
    [J]. HELIYON, 2023, 9 (11)
  • [2] Phase 1 Evaluation of the Bioequivalence and Drug-Drug Interaction Potential of a Novel Fixed-Dose Combination of Ezetimibe, Atorvastatin, and Amlodipine
    Lim, Hyung Soon
    Kim, Jae Hoon
    Hong, Jang Hee
    Jung, Jin-Gyu
    Sunwoo, Jung
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024,
  • [3] Mechanistic Considerations About an Unexpected Ramipril Drug-Drug Interaction in the Development of a Triple Fixed-Dose Combination Product Containing Ramipril, Amlodipine, and Atorvastatin
    Hermann, Robert
    Gundlach, Kristina
    Seiler, Dan
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (11): : 1307 - 1315
  • [4] A NOVEL MECHANISTIC PHYSIOLOGICALLY BASED PHARMACOKINETIC-PHARMACODYNAMIC (PBPK-PD) MODEL TO ASSESS DRUG-DRUG INTERACTION (DDI) RISKS FOR ACID REDUCING AGENTS (ARA)
    Ezuruike, U.
    Yeap, Y.
    Hatley, O.
    Neuhoff, S.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S26 - S26
1